Purpose
To assess the clinical usefulness of chorioretinal biopsy in establishing a definitive diagnosis in intraocular lymphomas.
Design
Retrospective, noncomparative, consecutive diagnostic case series.
Methods
setting : Moorfields Eye Hospital, London, United Kingdom. patients : Twenty-nine consecutive patients presenting with severe uveitis that required an intraocular biopsy where underlying lymphoma was suspected. observation procedure : A retrospective review of a 15-year period (1999–2014) was undertaken of all patients that have undergone chorioretinal biopsy for suspected lymphoma at Moorfields Eye Hospital, London, United Kingdom. Patients were identified on the hospital’s computerized database. main outcome measures : Effectiveness of chorioretinal biopsy in establishing a definitive diagnosis or in excluding malignancy.
Results
A specific histologic diagnosis was made in 17 cases (59%) while in 9 cases the biopsy combined with clinical data was effective in excluding malignancy. In the 3 remaining cases, no specific diagnosis was made. No intraoperative complications were reported. Postoperative complications other than cataract included 2 vitreous hemorrhages and 2 retinal detachments. Of the 17 cases with a histologic diagnosis, 15 were obtained in eyes with marked vitritis, as opposed to 2 with minimal vitritis.
Conclusions
Chorioretinal biopsy provided a definitive diagnosis of lymphoma in 59% of cases and assisted in exclusion of a further 31% in this series. The level of vitritis appears to act as a strong index of likelihood in achieving a definitive histologic diagnosis.
Obtaining intraocular biopsy specimens can be critical to the diagnosis and management of clinical cases where there is diagnostic uncertainty or where a tissue diagnosis is required. In such cases, mainly presenting with intraocular inflammation, the underlying etiology may be unclear, with malignancy a possibility. In these situations systemic investigations and noninvasive intraocular investigations such as ultrasound or fluorescein angiography may be insufficient to confirm or exclude malignancy, and taking affected tissue is required. Most commonly a vitreous biopsy is considered in the first instance, but it may prove inconclusive, in which case a chorioretinal biopsy may be useful in confirming or excluding malignancy. Despite this invasive investigation’s being technically difficult owing to the relatively inaccessible location and having potentially sight-threatening complications, it may be the only way of providing a histologic diagnosis. Biopsy of retinal and choroidal lesions can be achieved by a variety of external (transscleral fine needle aspiration or transscleral external biopsy) and internal (transvitreal fine needle aspiration or vitrectomy-assisted biopsy) approaches. However, to obtain a large tissue specimen in order to maximize diagnostic likelihood, transvitreal approaches have been used.
This study looks at the outcome of 29 consecutive retinal, choroidal, or chorioretinal biopsies performed in 29 patients for diagnostic reasons by the Vitreoretinal Surgical Unit at Moorfields Eye Hospital from 1999 to 2014.
The purpose of this study is to evaluate the clinical usefulness of this surgical investigation in establishing a definitive diagnosis in cases where lymphoma was suspected.
Patients and Methods
Patients
All choroidal, retinal, or chorioretinal biopsies performed at Moorfields Eye Hospital over a 15-year period from 1999 to 2014 were identified on the hospital’s computerized database. Those where the diagnosis of lymphoma was suspected were included in this series. Previous series from this hospital have been described and overlap some of these cases. Cases of vitreous biopsy alone were not included in this series. This study received a prospective international review board approval for this retrospective, noncomparative, consecutive diagnostic case series (Research and Development, Moorfields Eye Hospital NHS Foundation Trust).
Vitritis Grading
Severity of vitritis is divided into 2 categories, termed “ minimal ” or “ marked .” The distinction is based on the 1985 classifications by Nussenblatt. In this article minimal includes score 0 and 1, that is, nil and minimal or grade 0 and trace. All other categories are pooled as marked. The demarcation clinically as minimal implies no obstruction to features of the vessel margins and marked implies any obstruction to observation of clinical features of the fundus, including the vessels.
Surgical Techniques
The surgical approach was determined by the anatomic location of the lesion to be biopsied, whether primarily retinal or choroidal. The surgical techniques performed to obtain the biopsy specimen were previously described. General anesthesia was performed in all cases. An external approach was used in 1 case while an internal approach was used in 28 cases. The only technical difference regarding the internal approach relative to previous descriptions was the use of 23 gauge vitrectomy instead of 20 gauge in the more recent cases. At the time of the removal of the specimen from the eye, 1 of the ports was enlarged. Some patients had a formal diagnostic vitrectomy, including the collection of both an undiluted sample at the beginning of the surgery and the contents of the vitrectomy cassette, which was centrifuged to concentrate the cells for analysis.
Laboratory Techniques
Intraocular biopsies tend to be smaller than other types of biopsy and not always amenable to conventional handling techniques. The following is an overview of the general techniques applied to the cases in this series, but there may have been slight variations for individual cases.
Tissue specimens (for histology) were placed in 10% neutral buffered formalin at the time of surgery. Following fixation they were examined macroscopically, placed in tissue cassettes, and processed using automated equipment (the processor in use changed over time). The blocks were embedded in paraffin wax and 4 μm sections were cut. All specimens had at least 1 section stained with hematoxylin-eosin for initial examination, with other histochemical stains (such as periodic acid-Schiff for basement membrane) being requested based on specimen type and clinical information.
Any vitreous (cytology) specimens submitted along with the tissue specimens were handled using a variety of methods, depending on factors such as (but not limited to) the following: (1) clinical information; (2) whether the specimen was submitted fresh (unfixed) or in formalin; (3) whether any particulate material was seen in the specimen receptacle; and (4) volume of material received. Generally speaking, particulate material was fixed and processed as tissue, smear cytology preparations were made from fluid received, and a proportion of any fresh vitreous received was frozen to allow the opportunity for subsequent molecular studies, volume permitting.
Any immunohistochemistry required was performed on a Dako Autostainer (Agilent Technologies, Denmark) or, more recently, a Leica Bond (Leica Microsystem, Germany) immunostainer using retrieval methods, antibody dilutions, and protocols appropriate to the required antibody.
Results
Of the 29 patients listed for chorioretinal biopsy, 5 had a retinal biopsy only and 3 choroidal only, while 21 had chorioretinal biopsy, as documented in the surgical notes ( Table ). Eighteen of the total 29 patients received a combined vitreous and chorioretinal biopsy while 11 patients had a chorioretinal biopsy alone as a primary diagnostic procedure. Fifteen of the total 29 patients had previously had an inconclusive biopsy; of those, 12 had a vitreous biopsy alone, 2 had vitreous and chorioretinal biopsies, and 1 had vitreous and retinal biopsies. There were 21 female and 8 male patients, and their age range was 23–86 (median 68) years. The follow-up period was between 6 and 104 months (median 32 months).
Case No/ Sex, Age | Previous Inconclusive Biopsy | Grade of Vitritis Minimal/Marked | Vitreous Biopsy at Time of Chorioretinal Biopsy (Yes/No) (Diagnosis +/−) | Pathologic Diagnosis | Complications | Treatment | Follow-up (Months) | Preoperative BCVA | Final BCVA |
---|---|---|---|---|---|---|---|---|---|
1/ F, 49 | Vitreous + retinal | Marked | Yes + | Diffuse large B cell lymphoma | Cataract | Chemotherapy + radiotherapy | 18 | CF | CF |
2/ F, 40 | Vitreous | Marked | Yes − | None b | Phthisis | None | 32 | PL | Prosthesis |
3/ F, 61 | None | Minimal | Yes + | Toxoplasma chorioretinitis | Cataract | Azithromycin | 104 | 6/60 | 6/24 |
4/ F, 75 | None | Minimal | Yes − | None | None | None | 12 | CF | CF |
5/ F, 85 | None | Minimal | No | Lymphoma excluded | None | None | 34 | CF | CF |
6/ M, 68 | Vitreous | Marked | No | Diffuse large B cell lymphoma | Cataract | Chemotherapy + radiotherapy | 21 | HM | PL |
7/ F, 78 | Vitreous | Marked | Yes − | Extranodal marginal zone lymphoma MALT | None | Chemotherapy + radiotherapy | 22 | 6/60 | HM |
8/ F, 46 | None | Minimal | No | None b | None | Chemotherapy + radiotherapy | 53 | 1/60 | 1/60 |
9/ M, 70 | None | Marked | Yes − | Lymphoplasmacytic lymphoma | VH | Chemotherapy + radiotherapy | 13 | 6/12 | 6/24 |
10/ M, 57 | None | Minimal | No | Lymphoma excluded | None | Steroids | 63 | 1/60 | 6/60 |
11/ F, 76 | None | Minimal | Yes − | Lymphoma excluded | None | Steroids | 72 | 6/36 | 6/12 |
12/ F, 53 | Vitreous + Chorioretinal | Marked | Yes − | Diffuse large B cell lymphoma | VH | Chemotherapy + radiotherapy | 69 | CF | PL |
13 a / M, 86 | Vitreous | Marked | Yes + | Diffuse large B cell lymphoma | None | Chemotherapy | 37 | 1/60 | 1/60 |
14/ M, 32 | Vitreous | Marked | No | Unspecified gram-negative infection | None | Steroids (topical); ciprofloxacin (systemic) | 15 | 2/60 | 6/18 |
15/ M, 55 | Vitreous | Marked | Yes − | Extranodal marginal zone lymphoma MALT | Cataract | Chemotherapy + radiotherapy | 77 | 6/60 | 6/60 |
16/ F, 68 | Vitreous + Chorioretinal | Marked | No | Lymphoma excluded | None | Steroids | 36 | HM | 3/60 |
17/ F, 81 | None | Minimal | Yes − | Lymphoma excluded | Cataract | Intravitreal steroid | 66 | CF | CF |
18/ F, 81 | Vitreous | Marked | Yes − | Diffuse large B cell lymphoma | None | Chemotherapy + radiotherapy | 54 | CF | CF |
19/ M, 67 | Vitreous | Marked | Yes − | Diffuse large B cell lymphoma | None | Chemotherapy | 36 | 6/12 | 6/12 |
20/ F, 73 | Vitreous | Marked | No | Lymphoma excluded | None | None | 46 | HM | HM |
21/ M, 78 | Vitreous | Marked | Yes − | Toxoplasma chorioretinitis | RD | Azithromycin | 37 | HM | 2/60 |
22/ F, 67 | None | Minimal | No | Lymphoma excluded | None | None | 6 | CF | CF |
23/ F, 63 | None | Minimal | Yes − | Lymphoma excluded | None | Steroids | 14 | HM | NLP |
24/ F, 70 | Vitreous | Marked | Yes − | Diffuse large B cell lymphoma | None | Chemotherapy + radiotherapy | 11 | HM | 6/60 |
25/ F, 23 | None | Marked | No | Epithelioid melanoma | None | None | 10 | 2/60 | Prosthesis |
26/ F, 68 | Vitreous | Marked | No | Toxoplasma chorioretinitis b (PCR positive) | None | Azithromycin | 16 | 6/9 | 2/60 |
27/ F, 62 | None | Marked | Yes − | Diffuse large B cell lymphoma | RD | Chemotherapy + radiotherapy | 7 | HM | PL |
28/ F, 65 | None | Minimal | Yes − | Metastatic small cell carcinoma within the retina/subretina | None | Chemotherapy | 8 | PL | PL |
29/ F, 81 | None | Minimal | No | Lymphoma excluded | None | None | 9 | 6/9 | 6/9 |